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Abstract
Introduction: Restless legs syndrome (RLS) affects 5–15% of adults, but is often unrecognized and consequently misdiagnosed. The
International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common
treatment for RLS is levodopa, but this may lead to augmentation of symptoms. Pramipexole has been developed as an alternative
treatment for patients diagnosed with RLS.
Aims: The objective of this article is to review the evidence of the effectiveness of pramipexole for the clinical management of patients
with RLS.
Evidence review: There is clear evidence that pramipexole reduces the leg movements associated with RLS, as measured by
improvements in both the IRLS and the Clinical Global Impression (CGI) score. There is also moderate evidence that the drug improves
sleep quality. Pramipexole clearly improves the anxiety and depression often associated with RLS. Augmentation may be associated with
pramipexole treatment, but the evidence is contradictory and augmentation may be more associated with patients pretreated with levodopa
or with patients with primary RLS rather than those with secondary RLS. Pramipexole therapy appears to be well tolerated, with only mild-
to-moderate adverse events reported.
Outcomes summary: Pramipexole reduces leg movements in RLS, and is well tolerated. Further investigation is required to confirm the
preliminary evidence that pramipexole restores normal sleep architecture and restores a normal quality of life in patients with RLS. Health
economic studies would be valuable in demonstrating the true impact of pramipexole on the social burden of RLS.
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Outcome measure Evidence Implications
Patient-oriented evidence
Significant reduction in leg movements during sleep Clear Pramipexole is effective
No serious adverse events during 3–6 weeks of therapy Clear Well tolerated in short-term treatment
Low-dose pramipexole improves sleep indices Clear Improves sleep, but questions arise over sleep efficiency and sleep
architecture
Low-dose pramipexole improves depression in patients with RLS Clear  Pramipexole reduces both sensorimotor and depressive symptoms
No serious adverse events over prolonged periods up to 2 years Moderate May be well tolerated as long-term treatment by the majority of patients
Pramipexole does not cause augmentation over periods in
excess of 2 years
Moderate  Evidence is divided on the extent of augmentation and whether or not
it varies in different patient groups
Core evidence outcomes summary for pramipexole in restless legs syndromeScope, aims, and objectives
To review the evidence of the effectiveness of pramipexole
(Boehringer Ingelheim) on outcomes and potential for clinical
management of patients with restless legs syndrome (RLS).
Methods
Searches of the English language medical literature were
conducted between December 14 and 21, 2004, on January 17,
2005, and on March 15, 2005 on the following databases:
• PubMed, www.ncbi.nlm.nih.gov/entrez, 1966 to date 
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm   
• NHS HTA, www.ncchta.org
• National Guidelines Clearinghouse, www.guideline.gov
• Cochrane Database of Systematic Reviews, www.cochrane.org
• Clinical Evidence, www.clinicalevidence.com
The results of the searches are summarized in Table 1. Review
articles, letters, and articles not directly linked to RLS were
excluded from analysis (see Editorial Information on inside back
cover).
Search terms used were: pramipexole and restless legs syndrome;
Mirapex and restless legs syndrome; restless legs syndrome;
restless legs syndrome and cost; review and methodology studies;
pramipexole, restless legs and randomized controlled trials;
Mirapex, restless legs and randomized controlled trials.
Disease overview
Characteristics of RLS
RLS or Ekbom’s syndrome (Ekbom 1945) is a sensory motor
disorder characterized by a compelling urge to move the limbs
(Thorpy et al. 2000), which is diagnosed on the basis of the patient’s
symptoms and history (Thorpy et al. 2000; Allen et al. 2003). It may
be accompanied by unpleasant creeping or twitching sensations in
the affected limbs and is often associated with paresthesias and
dysthesias (Chaudhuri et al. 2004). RLS is a progressive disease
with intermittent and fluctuating symptoms at the beginning, which
increase in severity over time (Allen et al. 2003).
The symptoms associated with RLS often intensify at rest,
particularly in the evening or at night, resulting in sleep
disturbances and insomnia (Lesage & Hening 2004; Silber et al.
2004). Patients are often unable to tolerate sedentary activities and
are prone to daytime sleepiness and general fatigue as well as
impaired cognitive function; some also experience pain in the
affected limbs. RLS may also give rise to anxiety, depression, and
a reduced quality of life (QOL) (Lesage & Hening 2004). According
to Thorpy et al. (2000), sleep disruption combined with difficulties
in tolerating sedentary activities can compromise an individual’s
lifestyle, perhaps leading to job loss and problems with
relationships. Overall, the symptoms associated with RLS can
result in patients being severely incapacitated, possibly leading to
serious socioeconomic effects for them, although no health
economic evaluations have been reported. Any new treatment for
RLS should therefore address the mood disorders associated with
RLS as well as the primary problem of restless legs.
Prevalence and etiology of RLS
Several studies suggest that 5–15% of the adult population is
affected by RLS, but that only those with moderate-to-severe
symptoms, perhaps 3% of adults, seek medical treatment
(Chaudhuri et al. 2004; Lesage & Hening 2004; Silber et al. 2004;
Thorpy et al. 2000). RLS has a variable age of onset, and can occur
in children, but its prevalence increases with age; women are also
more likely to develop RLS than men (Chaudhuri et al. 2004). Up to
40% of patients with severe RLS experienced their first symptom
before the age of 20 years. The condition may be exacerbated by
stress and psychiatric conditions. RLS can be classified as primary
or secondary, both having similar symptoms. Primary RLS appears
to be of genetic origin, with a positive family history in 60% of cases
(Thorpy et al. 2000). According to Chaudhuri et al. (2004), secondary
RLS has a faster rate of progression than primary RLS and may be
associated with a number of conditions including: central iron
deficiency (sometimes without significant anemia), neurologic
lesions of the spinal cord and peripheral nerves, pregnancy, and
end-stage renal disease. Recently, it has been reported that there is
a bilateral increase in the gray matter of the pulvinar nucleus of the
thalamus in patients with idiopathic RLS, but it is not known if this is
involved in the pathogenesis of RLS or is a consequence of an
increase in afferent input due to RLS (Etgen et al. 2005).
Pathophysiology of RLS
There is substantial evidence to support the central role of
dopaminergic systems in the pathophysiology of RLS; for example
a mild reduction in dopamine levels has been observed in the
nigrostriatal pathway in patients with periodic limb movement
disorder (PLMD) and RLS (Ruottinen et al. 2000). This is supported
by the fact that RLS may be induced or worsened by a number of
drugs including tricyclic antidepressants (probably acting
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Number of records
Category Full papers Abstracts
Initial search 31 0
records excluded 21
records included 10
Additional studies identified 1 6
Level 1 clinical evidence 0 0
Level 2 clinical evidence 1 6
Level ≥3 clinical evidence 10 0
trials other than RCT 10 0
case reports 00
Economic evidence 0 0
RCT, randomized controlled trials.
Table 1 | Evidence base included in the review37
nonspecifically to block uptake of amines by nerve terminals),
selective serotonin reuptake inhibitors (SSRIs) [probably due to
dopamine-dependent side effects of SSRIs (Damsa et al. 2004)],
and dopamine antagonists (Thorpy et al. 2000). This indicates that
dysfunction of central dopaminergic systems of neurons may be
implicated in the pathophysiology of RLS. However, Stiasny-
Kolster et al. (2004b) indicate that imaging studies and analysis of
dopamine metabolites do not provide evidence for either a
dopaminergic deficit or neurodegeneration in the basal ganglia. 
Levodopa and dopamine agonists are known to be efficacious in
RLS (Akpinar 1982), while dopamine antagonists worsen the
syndrome. Furthermore, dopamine levels have a known circadian
rhythmicity and RLS symptoms coincide with lower central
dopamine levels (Sowers & Vlachakis 1984). However, this could
imply a functional impairment of the dopaminergic system or a
modulating influence on it, since melatonin inhibits central
dopamine secretion during daytime and is itself increased at night
(Stiasny-Kolster et al. 2004b). 
Tyrosine hydroxylase, the rate-limiting enzyme for the synthesis of
dopamine, requires iron as a cofactor, and it has been suggested
that lack of iron availability in the central nervous system (CNS)
affects dopamine metabolism (Happe & Trenkwalder 2004). In
patients with RLS, there is reduced staining for ferritin receptors in
the substantia nigra, perhaps due to an inadequate increase in iron
regulatory proteins that induce ferritin-receptor synthesis (Earley et
al. 2000). Furthermore, Kotagal and Silber (2004) have recently
demonstrated that iron deficiency and a positive family history are
characteristic of childhood-onset RLS. These findings clearly
indicate that brain iron depletion may be one cause of abnormally
low dopamine levels, which have a central role in the
pathophysiology of RLS. Alternatively, these effects could be due to
compromised iron acquisition in neuromelanin cells, which may
disrupt dopaminergic mechanisms (Stiasny-Kolster et al. 2004c).
Recent studies suggest that RLS may, in part, be a pain disorder
(Stiasny-Kolster et al. 2004c). In patients with RLS it has been
shown that there is profound hyperalgesia to punctate stimuli,
which may be improved by dopaminergic drugs. This may be due
to abnormal sensory input and/or altered descending inhibition
from the supraspinal dopaminergic system. 
Underrecognition and misdiagnosis of RLS
Because RLS is not well known and frequently unrecognized, it is
often misdiagnosed—only about 13% of patients presenting to
primary care physicians (PCPs) are accurately diagnosed (Chaudhuri
et al. 2004)—patients often receive either no treatment or drugs to
alleviate the sleep disorder rather than the underlying condition. 
PLMD, or nocturnal myoclonus, is distinguishable from RLS, but is
often associated with it in the form of periodic limb movements of
sleep (PLMS) (Lesage & Hening 2004). PLMS can occur in healthy
individuals and in patients with a range of disorders and is not
always associated with RLS (Montplaisir et al. 1997). Furthermore,
PLMD is polysomnographically distinct from RLS with more
spontaneous electroencephalogram (EEG) arousals occurring in
RLS than PLMD (Eisenehr et al. 2003). 
Neither RLS nor PLMS should be confused with akathisia (inability
to sit or stand still) in which patients complain of restlessness
accompanied by movements such as fidgeting of the legs, rocking
from foot to foot, pacing, or inability to sit or stand. Although
akathisia can occur spontaneously, it is most commonly observed
as a side effect of antipsychotic medications (neuroleptics) (Barnes
1987) and has no circadian rhythmicity (Walters et al. 1991).
A multinational questionnaire survey of more than 23 000 subjects
and their PCPs (n=182) highlighted the extent of the underrecognition
of RLS, in which almost 10% of subjects reported weekly RLS
symptoms (Hening et al. 2004b). Bias was reduced in the survey
since neither the PCPs nor the patients were made aware of the
subject of the investigation until after they had agreed to participate.
A sufferer subgroup of 551 patients who warranted treatment for RLS
was identified on the basis of at least twice-weekly symptoms with
appreciable negative impact on QOL. Of the subgroup, 357 (65%)
reported that they had consulted a physician, and only 46 of these
357 (13%) reported being diagnosed with RLS. PCPs reported that
209 (38%) of RLS patients consulted them about associated
symptoms, but only 52 (25%) had been given a diagnosis of RLS. 
In most countries regardless of diagnosis, the majority of RLS
patients were prescribed therapies inappropriate for the treatment
of RLS. These data highlight the need to increase awareness
among both patients and physicians of how RLS presents, to make
physicians more aware of how it is diagnosed and the medications
that are most effective for its treatment. 
Assessment and diagnosis of RLS
In 2003 the International RLS Study Group (IRLSSG) established
four criteria by which RLS can be easily recognized by the PCP
(Table 2). They also developed additional criteria for the diagnosis
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Criteria Description
Criterion 1 A compelling urge to move the legs, usually accompanied or caused by uncomfortable (paresthesias) and unpleasant (dysesthesias)
sensations in the legs—sometimes the urge to move occurs without the unpleasant sensations and sometimes the arms or other body
parts are involved in addition to the legs
Criterion 2 The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
Criterion 3 Symptoms are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
Criterion 4 Symptoms are worse in the evening and at night
Table 2 | Essential diagnostic criteria for restless legs syndrome. Based on Allen et al. (2003), Chaudhuri et al. (2004),
and Thorpy et al. (2000)of RLS in cognitively impaired elderly and in children. Several rating
scales and objective tests have also been developed to determine
the severity of RLS. The International Restless Legs Scale (IRLS,
occasionally known as the RLS Rating Scale or RLSRS), developed
and validated by the IRLSSG (2003), consists of 10 items each
rated on a 5-point severity scale. In a small study of 30 patients the
IRLS was shown to correlate significantly with other objective
measures of RLS such as various measures of motor dysfunction in
sleep/wakefulness during polysomnography (PSG) the Suggested
Immobilization Test (SIT), the Periodic Leg Movement of Sleep
index (PLMS-index), the PLMS-arousal index during PSG, and the
Periodic Leg Movement of Wakefulness (PLMW) during SIT (SIT-
PLMW) (Garcia-Borreguero et al. 2004). 
Most cases of RLS can be diagnosed by taking a thorough clinical
history and conducting a physical examination to rule out other
disorders, particularly neurologic and vascular disorders, and to
identify secondary causes (Thorpy et al. 2000). Laboratory tests
may then reveal other possible secondary causes such as uremia
or low ferritin levels (<50mcg/L). It is not routine to refer patients for
a sleep study since it should be possible to diagnose RLS on the
basis of the patient’s history and additional clinical findings.
However, if PSG is thought necessary it will involve monitoring a
number of physiologic variables during sleep, including brain
electrical activity using an EEG; eye movements by
electroocculography; jaw and leg muscle activity/movement by
electromyography; heart activity by electrocardiography; airflow
using a nasal thermistor; respiratory effort using piezo crystal
transducers attached to bands around the chest and abdomen;
and oxygen saturation using a pulse oximeter. These are research
methods that are being used to help with the differential diagnosis
of RLS from other related disorders. 
Current therapy options
Various advisory guidelines and algorithms for the management of
RLS are currently available (Thorpy et al. 2000; Lesage & Hening
2004; Schapira 2004; Silber et al. 2004). However, there is no
widely approved agent available for the treatment of RLS.
Treatment varies according to RLS severity, for example
dopaminergic agents such as levodopa or a dopamine agonist may
be used in patients with intermittent RLS, while patients with severe
symptoms may require strong opioids (Thorpy et al. 2000).
However, treatment of RLS has typically involved the use of
benzodiazepines, which are anxiolytic and hypnotic agents, and
other sedative drugs that may provide symptomatic relief but do
not influence the course of RLS. 
Recently, dopaminergic agents have emerged as the treatment of
choice for RLS (e.g. Happe & Trenkwalder 2004). Among these, the
dopamine precursor levodopa is the only drug currently indicated
for RLS, but only in Germany, Austria, and Switzerland. Although
the efficacy of levodopa has been established, it is associated with
a high incidence of long-term adverse effects including
augmentation, whereby the symptoms of RLS are worsened by the
therapy, and increasing quantities of medication are required, often
earlier in the day. In vitro experiments with levodopa, which is a
dopamine precursor, suggested that it was toxic to dopamine
neurons, but this is not supported by in vivo studies (Ferraro et al.
2003; Mytilineou et al. 2003).
Accumulating data suggest that the dopamine agonists may
provide alternative therapy, with substantially lower augmentation
rates than levodopa (Lesage & Hening 2004). Furthermore, it has
been suggested that D3 dopamine receptor agonists have
neuroprotective effects since they increase the production of
dopamine neurotrophic factor in tissue culture (Carvey et al. 2001),
although this has recently been questioned (Clarke 2004).  
The nonergot D3 autoreceptor agonist pramipexole, which is
indicated for the treatment of Parkinson’s disease, is currently
being evaluated for RLS in phase III trials. Other dopamine agonists
which are currently being evaluated for RLS include the D2 agonists
ropinirole, which has recently been approved by the FDA (Anon.
2005) and rotigotine which is being investigated in a transdermal
patch delivery system in phase II studies. Recent trials on
cabergoline (Stiasny-Kolster et al. 2004d) and pergolide
(Trenkwalder et al. 2004) have also been reported. The
dopaminergic treatment of RLS and PLMD has recently been
reviewed (Hening et al 2004a). 
No comparative data on the relative efficacy, tolerability, and safety
of the dopamine agonists have yet been reported. However,
evidence is accumulating to show that different groups of
dopamine receptors may be functionally compartmentalized in the
brain (Black et al. 2002), and it has been suggested that D3
receptors in the mesolimbic system may have a specific role to play
in the pathophysiology of RLS (Montplaisir et al. 2000).
In addition to its affinity for D3 receptors, pramipexole is also a
potent D2 agonist (Black et al. 2002), which is why it is effective in
the treatment of movement disorders such as Parkinson’s disease,
and has the potential to be beneficial in the management of RLS
(Strange 2000). However, pramipexole has even higher affinity for
D3 receptors (5–10-fold more than D2 receptors), which means that
it may also have effects on mood via these receptors. When
compared with other D2-like receptors, D3 receptors are
differentially distributed in the mesolimbic/mesocortical system and
prefrontal cortex (Black et al. 2002), which is closely linked to the
emotional part of the brain, the limbic system, thereby playing a role
in control of mood. Thus pramipexole may have the clinical
potential to modify both the limb movements and mood changes
associated with RLS.
Unmet needs
Even in the small proportion of diagnosed cases of RLS, patients are
often only given symptomatic treatments, none of which treat the
underlying problem of RLS (Hening et al. 2004b). The only drug
currently licensed for RLS is levodopa. However, it is associated
with potential long-term adverse events, particularly those
associated with augmentation, for example involuntary movements,
nausea, vomiting, and postural hypotension. These adverse effects
limit the use of levodopa and are often worse than the symptoms of
RLS. An ideal drug for RLS would not only suppress RLS symptoms,
stop PLMs, but would also restore natural sleep, diminish the
depression and anxiety associated with RLS, and delay the
progression of the disease. New drugs that avoid the consequences
of the prolonged use of levodopa are therefore required for the
treatment of RLS, which is why the dopamine agonists, such as
pramipexole, are being evaluated for the treatment of RLS.
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Clinical evidence from pramipexole in RLS
Leg movements 
In early studies with pramipexole there was a reduction of the mean
ILRS score from 17 (SD 4.3) to 7.8 (SD 4.9) (P<0.0001) in a two-centre,
open-label, questionnaire-based study on 23 patients with RLS
(Becker et al. 1998). After at least 4 weeks of treatment with
pramipexole, 19 patients reported improvement as assessed by their
RLSRS scores. In another small open-label study of 16 patients both
nocturnal leg restlessness and nocturnal involuntary leg movements
were analyzed using a visual analog scale (VAS). Although the data
obtained were subjective, after 2–3 months’ treatment most patients
reported improvements in both these areas (Lin et al. 1998). A more
recent, retrospective study of 60 patients showed that pramipexole
was effective in controlling RLS in 67% of patients, partially effective
in 27%, and ineffective in 7% (Silber et al. 2003). In a short-term open-
label PSG on 17 patients, insufficiently treated with levodopa, a single
low dose (0.125–0.75 mg, mean 0.3±0.2 mg) of pramipexole in the
evening resulted in an improvement of their symptoms when rated on
the IRLS and was well tolerated (Stiasny-Kolster & Oertel 2004). PSG
recordings showed that patients experienced improvements in the
Periodic Limb Movement Index (PLMI) and PLMS as well as sleep-
onset latency, total sleep time, and sleep efficiency. 
Only three randomized controlled trials (RCTs) of pramipexole in RLS
have so far been reported [Montplaisir 1999; Partinen et al. 2004
(see also Prescott 2004); Högl & Poewe 2005a/Oertel & Stiasny-
Kolster 2005a,b]. In a 10-week, double-blind RCT Montplaisir (1999)
demonstrated that pramipexole reduced the PLMS-index to normal
values in a study of 10 patients. PLMW was also significantly
reduced (P=0.007). These results were supported by a study on 109
patients with idiopathic RLS who were enrolled into a double-blind,
single-center RCT, using comprehensive PSG techniques (Partinen
et al. 2004). The primary endpoint of the study was a reduction in
limb movements as assessed by the PLMI during time in bed.
Pramipexole showed excellent efficacy across the tested dose
range of 0.125–0.75 mg/day within 3 weeks of therapy and there
was a statistically significant reduction in the PLMI versus placebo
(P<0.0001). Clinical efficacy was greatest in patients receiving 0.5
and 0.75 mg pramipexole per day. With 0.125 mg pramipexole the
IRLS score was reduced by 60%, by 78% with 0.5 mg and 75% with
0.75 mg as compared with placebo (P<0.0001).
These data were reflected in the patients’ reported outcomes, using
CGI scores, 60% of whom reported “much” to “very much”
improvement with 0.125 mg pramipexole, up to 85% with 0.5 mg
and 83% with 0.75 mg. A further study in 345 patients with
idiopathic RLS showed that pramipexole significantly (P<0.0001)
improved symptoms when measured on a CGI scale and a VAS
over a 6-week period (Oertel & Stiasny-Kolster 2005a). Pramipexole
produced a significant (P<0.0001) benefit after only 1 week of
treatment when measured by patient global improvement (PGI)
ratings and at the end of 6 weeks significantly (P<0.0004) more
patients in the pramipexole group experienced an improvement in
symptoms when compared with the placebo group (Oertel &
Stiasny-Kolster 2005b). Furthermore, Högl and Poewe (2005a) have
shown, in a substudy, that a single dose of pramipexole
(0.125–0.75 mg) per day significantly (P<0.0001) reduced the
severity of daytime and nighttime RLS over the course of 24 h.
Sleep quality
There is some evidence that the effect of pramipexole in reducing
leg movements has a benefit to patients in terms of improved
sleep quality. 
In a small open-label trial on 16 patients in a sleep disorder center,
insomnia was analyzed using a VAS. Although the data obtained
were subjective, after 2–3 months the majority of patients (11 of
16) reported clinically significant improvements in insomnia (Lin et
al. 1998). This is supported by a PSG study that demonstrated
moderately improved sleep quality, although there were some
changes in sleep architecture (Saletu et al. 2002). Furthermore,
Högl and Poewe (2005b) showed, in an RCT on 345 patients with
RLS, that a single dose (0.175–0.75 mg) of pramipexole over a
24–h period significantly improved sleep compared with placebo
(P=0.0001) over a 6-week period. A retrospective study of 24
patients with RLS also indicated that pramipexole (0.125–0.75 mg)
did not increase the risk of daytime sleep episodes (Stiasny-
Kolster et al. 2000).
Further studies on sleep-onset latency, sleep quality, sleep
efficiency, and sleep architecture would be welcome to confirm
that patients with RLS treated with pramipexole experience good
quality sleep and do not have daytime fatigue after treatment, and
to test whether different groups of patients respond differentially
to treatment. 
Anxiety and depression
Ideally, drugs used for the treatment of RLS should also address
the associated anxiety and depression. There is clear evidence for
pramipexole on this outcome. The PSG study on 11 patients with
RLS by Saletu et al. (2002) indicated that after 4 weeks of
pramipexole therapy (0.28±0.1mg), patient self-rating depression
scores improved by 23%. The study on 345 patients with RLS
(Stiasny-Kolster & Oertel 2005) indicated that pramipexole
significantly (P<0.0001) improved severe mood disturbances and
depressive symptoms when compared with placebo.
Clinical trials will need to be carefully designed to clarify whether
anxiety and depression are part of RLS or merely its sequelae.
Studies on the effects of pramipexole on mood disturbances would
also be useful to ascertain its impact on the full spectrum of
consequences of RLS.
Quality of life
Clinical trials to determine the impact of pramipexole on QOL have
not yet been reported. Such studies are important because
undiagnosed or misdiagnosed RLS leads to a decline in QOL, as a
result of physical discomfort, sleep disturbances, and fatigue. 
Adverse events and tolerability
The occurrence of adverse events associated with pramipexole is
not always fully described, but according to Silber et al. (2003) 40%
of patients experienced mild side effects. The most common
adverse events include mild nausea and daytime fatigue, insomnia,
constipation, dyspepsia, loss of appetite, tachycardia, and
dizziness (Becker et al. 1998; Comella 2002; Ferini-Strambi 2002;
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patients. In the study by Partinen et al. (2004) safety and tolerability
were reported to be favorable at all dose levels and no serious
adverse events were reported in this or other reports (e.g. Oertel &
Stiasny-Kolster 2005a).  
Augmentation 
There is some evidence from observational studies on the
incidence of augmentation with pramipexole in short- and longer-
term treatment. A follow-up study on seven of the patients from the
RCT conducted by Montplaisir et al. (1999) was carried out for a
mean duration of 7.8 months using home questionnaires
(Montplaisir et al. 2000). This indicated that there was no decrease
in the therapeutic effect of pramipexole, although there was a
progressive increase in the severity of leg movements before taking
a single dose of pramipexole (0.375–1.5mg/day) before bedtime.
Similarly, Ferini-Strambi (2002) showed only an 8% augmentation
rate in 60 patients over a 6-month period.
Longer-term studies indicate a higher rate of augmentation. In a
retrospective study, augmentation developed in 43% of 83
patients over 39.2 months (±20.9 months) after treatment with
pramipexole (52 patients), ropinirole (19 patients), or pergolide
(12 patients) (Ondo et al. 2004). Efficacy was maintained by
moderate increases in dose (P<0.01) although absolute values
were not reported. These data suggest that patients with
secondary RLS are less likely to develop augmentation than
those with primary RLS. However, these data must be treated
with some reserve, since most of the patients were either not on
monotherapy or altered their dopaminergic medication during
their course of treatment. 
Winkelman and Johnston (2004) reported a naturalistic case
series for the effects of pramipexole. Fifty-nine patients met the
inclusion criteria and were retrospectively analyzed after at least
6 months (mean±SD=21.2±11.4 months). Their findings showed
that augmentation developed in 32% of patients and tolerance in
46% of patients. However, they also found that previous
augmentation (n=38) or tolerance (n=34) with levodopa
significantly increased the probability of both augmentation and
tolerance to pramipexole. 
In contrast, a study in 60 patients with RLS found that
augmentation developed in 20% in the first year and 30% after 2
years, but that the risk of augmentation tapered off after 2.5 years
of treatment with pramipexole, and augmentation did not appear to
be associated with previous levodopa/carbidopa or pergolide
treatment (Silber et al. 2003).
From these findings, it is clear that comparative studies on
augmentation of RLS by pramipexole are required to determine its
time course and its prevalence amongst different groups of
patients. 
Resource utilization
The economic effects of misdiagnosed or undiagnosed RLS have
not yet been reported. However, given that 5–15% of the adult
population is affected, the direct and indirect economic
consequences of the disease are likely to be significant.
It can be predicted that earlier recognition of RLS, particularly by
PCPs, would reduce the number of undiagnosed and
misdiagnosed cases of RLS, with a consequent reduction in the
misapplication of resources. The IRLS (IRLSSG 2003) provides
PCPs with an adequate tool for the evaluation of the severity of
RLS, which, if widely introduced, would reduce the social,
economic, and therapeutic impacts of RLS. This is important from
the standpoint of both patients and care providers. Studies on the
pharmacoeconomics and QOL of treatment with pramipexole are
needed to determine the impact of the drug on the burden of RLS.
Patient group/population
Studies to date suggest that pramipexole should be a first-line
choice for all patients with RLS. However, pramipexole may be less
effective in patients with primary RLS (Ondo et al. 2004) who have
previously been treated with other dopaminergic substances since
they may be more likely to develop augmentation of the disease
(Winkelman & Johnston 2004). 
Outcomes summary
RLS is a relatively common condition, which is frequently
misdiagnosed. Thus, there is a need for improved diagnosis in
primary care so that it can be treated appropriately, rather than
being considered as primarily a sleep disorder. Given the potential
economic and social costs of RLS, its severity needs to be
recognized at an early stage by PCPs, preferably using the IRLS,
which is specifically designed for this purpose (IRLSSG 2003).
Once a correct diagnosis has been achieved, the only drug
currently indicated for the treatment of RLS is levodopa, but this is
associated with a high incidence of adverse events (e.g.
augmentation), which significantly limit its use. Nevertheless, in
those patients where it does have utility, new treatments need to
demonstrate at least equivalent efficacy to levodopa in terms of
symptom relief and improved QOL, coupled with better tolerability
and less chance of augmentation. Furthermore, because of the
relatively low acquisition cost of levodopa, the direct and indirect
economic consequences of any therapeutic benefit of new
alternatives need to be quantified to assess the true impact on RLS
management. 
There is clear evidence that pramipexole is effective in reducing the
leg movements associated with RLS, the major outcome measure
of the disease.  From the patients’ perspective there is clear
evidence that it improves the quality of sleep. It is well tolerated in
short-term treatment (up to 6 weeks) and there is some evidence
that this tolerability profile is maintained in the longer term (>2
years’ treatment). There is also clear evidence that it improves
depressive symptoms associated with RLS.
It appears that pramipexole may substantially lower augmentation
rates compared with levodopa. At present, the lack of direct
evidence makes it difficult to evaluate the impact of pramipexole on
the economic and QOL burden of RLS. However, if future studies
confirm the effectiveness of pramipexole in the treatment of RLS
(particularly on sleep outcomes), its favorable tolerability profile,
and its effect on QOL, then the drug may offer QOL and economic
benefits compared with levodopa. 
Pramipexole | outcomes review
© 2005 Core Medical Publishing Limited 4041
Future studies need to demonstrate that pramipexole restores
normal sleep architecture, prevents anxiety and depression
associated with RLS, and improves patient QOL. Health economic
studies would also be welcome to show the true economic and
social burden of RLS.
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